Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers..
Hepatology. 39(6), 1739-45.
(2004). Non alcoholic fatty liver disease and metabolic syndrome..
Hippokratia. 13(1), 9-19.
(2009). Non small cell lung cancer in the elderly: clinico-pathologic, management and outcome characteristics in comparison to younger patients..
J Chemother. 21(5), 573-83.
(2009). Non traumatic liver herniation due to persistent cough mimicking a pulmonary mass..
Hippokratia. 17(4), 376-7.
(2013). Non tumoral hyperserotoninaemia responsive to octreotide due to dual polymorphism in UGT1A1 and UGT1A6..
Hormones (Athens). 11(1), 104-8.
(2012). Nonalcoholic fatty future disease..
Metabolism. 65(8), 1007-16.
(2016). Non-alcoholic fatty liver disease: an emerging predictor of stroke risk, severity and outcome..
Eur J Neurol. 25(4), 610-611.
(2018). Nonalcoholic fatty liver disease and Helicobacter pylori infection. Is it time to address this potential relationship?.
Curr Vasc Pharmacol.
(2023). Nonalcoholic fatty liver disease and hepatocellular carcinoma:Insights in epidemiology, pathogenesis, imaging, prevention and therapy..
Semin Cancer Biol. 93, 20-35.
(2023). Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications..
Diabetes Obes Metab. 24(9), 1702-1720.
(2022). Nonalcoholic fatty liver disease and polycystic ovary syndrome..
Ann Hepatol. 14(6), 941-3.
(2015). Nonalcoholic fatty liver disease and severity of cardiovascular disease manifestations..
Angiology. 64(8), 572-5.
(2013). Nonalcoholic fatty liver disease and statins..
Metabolism. 64(10), 1215-23.
(2015). Non-alcoholic fatty liver disease in children..
Curr Vasc Pharmacol.
(2022). Nonalcoholic fatty liver disease in males with low testosterone concentrations..
Diabetes Metab Syndr. 14(5), 1571-1577.
(2020). Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options..
Curr Vasc Pharmacol. 10(2), 162-72.
(2012). Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis..
Hormones (Athens). 13(4), 519-31.
(2014).
(2019). Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome..
Hum Reprod. 31(6), 1347-53.
(2016). Nonalcoholic fatty liver disease: Is it time for combination treatment and a diabetes-like approach?.
Hepatology. 68(1), 389.
(2018). Nonalcoholic fatty liver disease: lifestyle and quality of life..
Hormones (Athens).
(2021). Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease..
J Clin Gastroenterol. 46(4), 272-84.
(2012). Nonalcoholic fatty liver disease test: an external validation cohort..
Hormones (Athens).
(2023). Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines..
Curr Mol Med. 9(3), 299-314.
(2009). Non-alcoholic fatty liver disease through the female lifespan: the role of sex hormones..
J Endocrinol Invest.
(2022).